Drug Patents Expiring in 2037
1. List of Adlarity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10307379 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
| US9993466 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
| US10300025 | CORIUM | Donepezil transdermal delivery system |
Jul, 2037
(14 years from now) | |
| US11103463 | CORIUM | Methods for treating alzheimer's disease with donepezil transdermal system |
Jul, 2037
(14 years from now) | |
| US10016372 | CORIUM | Transdermal delivery systems with pharmacokinetics bioequivalent to oral delivery |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 11, 2025 |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE ingredient
Market Authorisation Date: 11 March, 2022
Treatment: A method of transdermal delivery of donepezil for treating mild, moderate and severe dementia of the alzheimer's type
Dosage: SYSTEM;TRANSDERMAL
ADLARITY family patents
26
United States
10
Japan
8
Korea, Republic of
5
China
5
Canada
5
Australia
5
European Union
2
Russia
2
Singapore
2
Mexico
2. List of Airduo Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
3. List of Akynzeo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11529362 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(14 years from now) | |
| US10624911 | HELSINN HLTHCARE | Physiologically balanced injectable formulations of fosnetupitant |
Jun, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 19, 2023 |
NCE-1 date: 2022-04-19
Market Authorisation Date: 19 April, 2018
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
AKYNZEO family patents
3
United States
3
European Union
2
Japan
1
Uruguay
1
Spain
1
Philippines
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
China
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
Singapore
1
Argentina
1
EA
1
Croatia
1
Korea, Republic of
1
Cyprus
1
Peru
1
Chile
1
Israel
1
Portugal
1
Taiwan
1
Mexico
1
Australia
1
Ecuador
1
South Africa
1
Colombia
1
Lithuania
1
Slovenia
4. List of Amzeeq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398641 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) | |
| US10849847 | JOURNEY | Compositions and methods for treating rosacea and acne |
Sep, 2037
(14 years from now) | |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 October, 2019
Treatment: Treatment of non-nodular acne vulgaris
Dosage: AEROSOL, FOAM;TOPICAL
AMZEEQ family patents
7
United States
1
Canada
1
Mexico
5. List of Armonair Digihaler drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10569034 (Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jul 9, 2024 |
| New Strength (NS) | Jul 9, 2024 |
| Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
6. List of Atorvaliq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(14 years from now) | |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION;ORAL
7. List of Auvi-q drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10688244 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(14 years from now) | |
| US10842938 | KALEO INC | Medicament delivery device and methods for delivering drugs to infants and children |
Dec, 2037
(14 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 10 August, 2012
Treatment: Method of treating an allergic reaction using an auto-injector
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
AUVI-Q family patents
6
United States
1
Canada
1
Japan
1
Australia
1
European Union
8. List of Azstarys drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10584112 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10759778 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(14 years from now) | |
| US10954213 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(14 years from now) | |
| US10858341 | COMMAVE THERAP | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(14 years from now) | |
| US10584113 | COMMAVE THERAP | Methylphenidate-prodrugs, processes of making and using the same |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 7, 2026 |
NCE-1 date: 2025-05-07
Market Authorisation Date: 07 May, 2021
Treatment: Treatment of attention-deficit hyperactivity disorder (adhd) with serdexmethylphenidate and dexmethylphenidate
Dosage: CAPSULE;ORAL
AZSTARYS family patents
16
United States
2
Israel
2
Australia
1
New Zealand
1
Korea, Republic of
1
China
1
Brazil
1
Canada
1
Mexico
1
Japan
1
European Union
9. List of Bludigo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(14 years from now) | |
| US11499050 | PROVEPHARM SAS | NA |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 8, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 2026-07-08
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
BLUDIGO family patents
3
United States
2
India
1
European Union
10. List of Brukinsa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11591340 | BEIGENE | NA |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
| New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with...
Dosage: CAPSULE;ORAL
BRUKINSA family patents
7
United States
2
China
2
Israel
2
Japan
2
Australia
1
Korea, Republic of
1
IB
1
Brazil
1
South Africa
1
Canada
1
Taiwan
1
Singapore
1
EA
1
Mexico
1
European Union
11. List of Cabometyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 17, 2028 |
| New Indication (I) | Sep 17, 2024 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma (rcc) in patients who have received prior anti-angiogenic therapy
Dosage: TABLET;ORAL
CABOMETYX family patents
19
United States
1
Russia
1
China
1
Canada
1
Morocco
1
European Union
12. List of Calcium Gluconate In Sodium Chloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130646 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(14 years from now) | |
| US10342813 | HQ SPCLT PHARMA | Calcium gluconate solutions in flexible containers |
Jul, 2037
(14 years from now) | |
Drugs and Companies using CALCIUM GLUCONATE ingredient
Market Authorisation Date: 29 October, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
CALCIUM GLUCONATE IN SODIUM CHLORIDE family patents
3
United States
13. List of Cequa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10918694 | SUN PHARM | Topical cyclosporine-containing formulations and uses thereof |
Feb, 2037
(13 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 14 August, 2018
Treatment: NA
Dosage: SOLUTION;OPHTHALMIC
CEQUA family patents
8
United States
2
Japan
2
Australia
1
Korea, Republic of
1
China
1
Russia
1
Israel
1
Brazil
1
South Africa
1
Canada
1
Singapore
1
Mexico
1
European Union
14. List of Definity drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789210 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(13 years from now) | |
| US10583208 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(13 years from now) | |
| US11529431 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(13 years from now) | |
| US11266750 | LANTHEUS MEDCL | Methods for making ultrasound contrast agents |
Mar, 2037
(13 years from now) | |
| US10588988 | LANTHEUS MEDCL | Methods and devices for preparation of ultrasound contrast agents |
May, 2037
(13 years from now) | |
Drugs and Companies using PERFLUTREN ingredient
Market Authorisation Date: 31 July, 2001
Treatment: Method of using the drug substance/drug product for ultrasound imaging
Dosage: INJECTABLE;INTRAVENOUS
DEFINITY family patents
19
United States
4
Israel
3
Korea, Republic of
3
China
3
Taiwan
3
Japan
2
Canada
2
Brazil
2
Singapore
2
EA
2
Mexico
2
Australia
2
European Union
15. List of Dextenza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Indication (I) | Oct 7, 2024 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Treatment of ocular itching associated with allergic conjunctivitis; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
DEXTENZA family patents
3
United States
16. List of Drizalma Sprinkle drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202772 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US10959982 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US10413525 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
| US9839626 | SUN PHARM | Duloxetine sprinkles |
Apr, 2037
(13 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 July, 2019
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS;ORAL
DRIZALMA SPRINKLE family patents
6
United States
1
India
1
European Union
17. List of Esbriet drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10188637 | GENENTECH INC | Granulate formulation of 5-methyl-1-phenyl-2-(1H)-pyridone and method of making the same |
Mar, 2037
(13 years from now) | |
Drugs and Companies using PIRFENIDONE ingredient
Market Authorisation Date: 11 January, 2017
Treatment: NA
Dosage: TABLET;ORAL
ESBRIET family patents
4
United States
2
China
2
Japan
2
European Union
1
Korea, Republic of
1
Poland
1
Spain
1
Israel
1
Canada
1
Argentina
1
Mexico
1
Australia
18. List of Evekeo Odt drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10441554 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(13 years from now) | |
| US11160772 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(13 years from now) | |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
EVEKEO ODT family patents
4
United States
19. List of Fintepla drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10947183 (Pediatric) | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Jun, 2037
(14 years from now) | |
| US11406606 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US11040018 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| US10603290 | ZOGENIX INC | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Mar 25, 2029 |
| New Product (NP) | Jun 25, 2023 |
| New Indication (I) | Mar 25, 2025 |
| Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seiz...
Dosage: SOLUTION;ORAL
FINTEPLA family patents
9
United States
2
Russia
2
Israel
2
Taiwan
2
Japan
2
Australia
1
New Zealand
1
Korea, Republic of
1
IB
1
China
1
South Africa
1
Canada
1
Singapore
1
Mexico
1
European Union
20. List of Firdapse drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
| Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
| New Patient Population (NPP) | Sep 29, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 2022-11-28
Market Authorisation Date: 28 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
FIRDAPSE family patents
3
United States
21. List of Fleqsuvy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446246 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(14 years from now) | |
| US11324696 | AZURITY | Suspensions and diluents for metronidazole and baclofen |
Sep, 2037
(14 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Indicated for the treatment of spasticity resulting from multiple sclerosis
Dosage: SUSPENSION;ORAL
FLEQSUVY family patents
11
United States
1
China
1
Canada
1
European Union
22. List of Fluorescein Sodium And Benoxinate Hydrochloride drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10293047 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) | |
| US10632197 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) | |
| US10842872 | BAUSCH LOMB IRELAND | Fluorescein and benoxinate compositions |
Nov, 2037
(14 years from now) | |
Drugs and Companies using BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM ingredient
Market Authorisation Date: 09 March, 2020
Treatment: Ocular examination, intraocular pressure measurement, or removal of foreign bodies or sutures, in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic ane...
Dosage: SOLUTION/DROPS;OPHTHALMIC
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE family patents
5
United States
1
China
1
Canada
1
European Union
23. List of Galafold drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(13 years from now) | |
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 10, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 10, 2025 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 2022-08-10
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients
Dosage: CAPSULE;ORAL
GALAFOLD family patents
6
United States
3
Taiwan
2
Korea, Republic of
2
China
2
Japan
1
European Union
24. List of Giapreza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11219662 | LA JOLLA PHARMA | Methods for treating hypotension in a patient that has received an ACE inhibitor by administering angiotensin II |
Jan, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 2021-12-21
Market Authorisation Date: 21 December, 2017
Treatment: Treating hypotension with angiotensin ii in a patient receiving an angiotensin converting enzyme inhibitor
Dosage: SOLUTION;INTRAVENOUS
GIAPREZA family patents
7
United States
1
Korea, Republic of
1
Brazil
1
Canada
1
Taiwan
1
Japan
1
Australia
1
European Union
25. List of Gloperba drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10226423 | ROMEG | Colchicine drug-to-drug interactions |
Dec, 2037
(14 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: NA
Dosage: SOLUTION;ORAL
26. List of Goprelto drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10933060 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10016407 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US11040032 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10231961 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10857095 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10894012 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10987347 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10973811 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US9867815 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10149843 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10420760 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| US10413505 | GENUS LIFESCIENCES | Pharmaceutical compositions and methods of using the same |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 14, 2022 |
Drugs and Companies using COCAINE HYDROCHLORIDE ingredient
NCE-1 date: 2021-12-14
Market Authorisation Date: 14 December, 2017
Treatment: Method for the induction of local anesthesia of the mucous membranes; Method of administering a local anesthetic prior to performing a diagnostic or surgical procedure on a subject with hepatic or ren...
Dosage: SOLUTION;NASAL
GOPRELTO family patents
14
United States
27. List of Hemady drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11304961 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| US10537585 | DEXCEL PHARMA | Compositions comprising dexamethasone |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Oct 3, 2026 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 03 October, 2019
Treatment: A method of treating adults with multiple myeloma using dexamethasone in combination with an anti-myeloma product
Dosage: TABLET;ORAL
HEMADY family patents
2
United States
1
Israel
28. List of Ingrezza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10857148 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US11040029 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10993941 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10912771 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10952997 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10857137 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| US10874648 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Oct, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: 2021-04-11
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; Method of administering valbenazine while avoiding concomitant use of ...
Dosage: CAPSULE;ORAL
INGREZZA family patents
25
United States
11
Japan
8
Australia
7
Korea, Republic of
6
China
6
Philippines
6
Canada
6
EA
6
Mexico
4
Singapore
1
Malaysia
29. List of Inlyta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Jan, 2037
(13 years from now) | |
Drugs and Companies using AXITINIB ingredient
Market Authorisation Date: 27 January, 2012
Treatment: Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
INLYTA family patents
8
United States
2
Japan
1
New Zealand
1
Korea, Republic of
1
China
1
Russia
1
Hong Kong
1
Philippines
1
Malaysia
1
Israel
1
Canada
1
Taiwan
1
Mexico
1
Australia
1
European Union
30. List of Katerzia drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10959991 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US11484498 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
| US11471409 | AZURITY | NA |
Oct, 2037
(14 years from now) | |
| US11364230 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10894039 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10952998 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
| US10695329 | AZURITY | Amlodipine formulations |
Oct, 2037
(14 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: Angina pectoris; Angina; A method of treating coronary artery disease; A method of treating hypertension; Treatment of hypertension; Method of treating hypertension
Dosage: SUSPENSION;ORAL
KATERZIA family patents
14
United States
3
European Union
2
Canada
1
China
1
Spain
1
Japan
31. List of Korlym drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10151763 | CORCEPT THERAP | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome |
Jan, 2037
(13 years from now) | |
| US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(14 years from now) | |
| US10842800 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(14 years from now) | |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
KORLYM family patents
13
United States
2
Korea, Republic of
2
Israel
2
Canada
2
Singapore
2
Mexico
2
Japan
2
Australia
2
European Union
1
China
1
Spain
32. List of Krazati drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10689377 | MIRATI THERAPS | KRas G12C inhibitors |
May, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 12, 2027 |
| Orphan Drug Exclusivity (ODE) | Dec 12, 2029 |
Drugs and Companies using ADAGRASIB ingredient
NCE-1 date: 2026-12-12
Market Authorisation Date: 12 December, 2022
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
KRAZATI family patents
7
United States
2
Japan
2
European Union
1
Korea, Republic of
1
China
1
Philippines
1
Chile
1
South Africa
1
Israel
1
Ukraine
1
Taiwan
1
Singapore
1
Brazil
1
Canada
1
Colombia
1
EA
1
Australia
33. List of Lexette drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10857159 (Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Aug 18, 2024 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: NA
Dosage: AEROSOL, FOAM;TOPICAL
34. List of Lonsurf drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10456399 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(13 years from now) | |
| US10960004 | TAIHO ONCOLOGY | Method for treating cancer patients with severe renal impairment |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
Market Authorisation Date: 22 September, 2015
Treatment: Method of treating cancer by detecting a creatinine clearance of a patient and administering lonsurf
Dosage: TABLET;ORAL
LONSURF family patents
4
United States
3
Japan
2
Korea, Republic of
1
New Zealand
1
Russia
1
South Africa
1
Ukraine
1
Taiwan
1
Morocco
1
Australia
1
European Union
35. List of Lupkynis drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11622991 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 2025-01-22
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
LUPKYNIS family patents
5
United States
2
Japan
1
Korea, Republic of
1
China
1
IB
1
Russia
1
Chile
1
Canada
1
South Africa
1
Brazil
1
Australia
1
European Union
36. List of Myfembree drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
| New Product (NP) | May 26, 2024 |
| M (M) | Jan 27, 2026 |
| New Indication (I) | Aug 5, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women
Dosage: TABLET;ORAL
MYFEMBREE family patents
16
United States
7
European Union
4
Japan
4
Australia
3
Canada
3
Morocco
3
Argentina
3
EA
3
Israel
2
China
2
Brazil
2
New Zealand
2
Mexico
1
Spain
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Croatia
1
Portugal
1
Taiwan
1
Lithuania
1
Slovenia
1
Hungary
37. List of Nuplazid drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10517860 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(13 years from now) | |
| US10953000 | ACADIA PHARMS INC | Combination of pimavanserin and cytochrome P450 modulators |
Mar, 2037
(13 years from now) | |
Drugs and Companies using PIMAVANSERIN TARTRATE ingredient
Market Authorisation Date: 29 April, 2016
Treatment: Treatment of hallucinations and delusions associated with parkinson's disease psychosis
Dosage: TABLET;ORAL
NUPLAZID family patents
8
United States
1
Sweden
38. List of Nuzyra drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10111890 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and uses thereof |
Aug, 2037
(14 years from now) | |
| US10383884 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| US10835542 | PARATEK PHARMS INC | 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP) |
Oct, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Oct 2, 2023 |
| Generating Antibiotic Incentives Now (GAIN) | Oct 2, 2028 |
Drugs and Companies using OMADACYCLINE TOSYLATE ingredient
NCE-1 date: 2027-10-03
Market Authorisation Date: 02 October, 2018
Treatment: Treatment of subjects having bacterial skin or skin structure infection; Treatment of community acquired bacterial pneumonia
Dosage: TABLET;ORAL
NUZYRA family patents
15
United States
4
Singapore
3
Taiwan
3
Australia
2
China
2
Russia
2
Philippines
2
Brazil
2
Canada
2
Mexico
2
Japan
2
European Union
39. List of Orgovyx drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10786501 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| US10449191 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| US11583526 | MYOVANT SCIENCES | Treatment of prostate cancer |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 2024-12-18
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
ORGOVYX family patents
16
United States
7
European Union
4
Japan
4
Australia
3
Canada
3
Morocco
3
Argentina
3
EA
3
Israel
2
China
2
Brazil
2
New Zealand
2
Mexico
1
Spain
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Croatia
1
Portugal
1
Taiwan
1
Lithuania
1
Slovenia
1
Hungary
40. List of Otiprio drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040004 | ALK ABELLO | Otic gel formulations for treating otitis externa |
Nov, 2037
(14 years from now) | |
Drugs and Companies using CIPROFLOXACIN ingredient
Market Authorisation Date: 10 December, 2015
Treatment: The treatment of acute otitis externa in patients 6 months of age and older due to pseudomonas aeruginosa and staphylococcus aureus
Dosage: INJECTABLE, SUSPENSION;OTIC
OTIPRIO family patents
4
United States
1
European Union
41. List of Oxbryta drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10493035 | GLOBAL BLOOD THERAPS | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Oct, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 25, 2026 |
| New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 2023-11-26
Market Authorisation Date: 25 November, 2019
Treatment: NA
Dosage: TABLET;ORAL
OXBRYTA family patents
7
United States
2
Israel
1
Brazil
1
Taiwan
1
Morocco
1
Argentina
1
Mexico
1
European Union
42. List of Pizensy drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10806743 | BRAINTREE LABS | Method of administering lactitol to reduce plasma concentration of lactitol |
May, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 12, 2025 |
Drugs and Companies using LACTITOL ingredient
NCE-1 date: 2024-02-13
Market Authorisation Date: 12 February, 2020
Treatment: Method of treating chronic idiopathic constipation in adult patients.
Dosage: FOR SOLUTION;ORAL
43. List of Procysbi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10328037 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10548859 (Pediatric) | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10143665 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
|
US10905662 (Pediatric) | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Feb, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
| Pediatric Exclusivity (PED) | Feb 14, 2023 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
44. List of Pylarify drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 2025-05-26
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION;INTRAVENOUS
PYLARIFY family patents
5
United States
2
Japan
1
Korea, Republic of
1
China
1
Canada
1
Singapore
1
European Union
45. List of Retevmo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112942 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172851 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| US10137124 | LOXO ONCOLOGY INC | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors |
Oct, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 8, 2025 |
| Orphan Drug Exclusivity (ODE) | Sep 21, 2029 |
Drugs and Companies using SELPERCATINIB ingredient
NCE-1 date: 2024-05-08
Market Authorisation Date: 08 May, 2020
Treatment: Treatment of adult patients with metastatic ret fusion-positive non-small cell lung cancer; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant m...
Dosage: CAPSULE;ORAL
RETEVMO family patents
12
United States
4
Japan
2
China
2
Morocco
2
Israel
2
European Union
1
Spain
1
Dominican Republic
1
Philippines
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Singapore
1
Argentina
1
EA
1
Croatia
1
Korea, Republic of
1
Peru
1
Chile
1
Portugal
1
Taiwan
1
Jordan
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
Colombia
1
Lithuania
1
Saudi Arabia
1
Tunisia
1
Slovenia
1
Hungary
46. List of Reyvow drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 2024-02-01
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
REYVOW family patents
3
United States
3
China
2
Japan
2
Korea, Republic of
1
Spain
1
Dominican Republic
1
Philippines
1
Moldova, Republic of
1
Denmark
1
RS
1
Poland
1
Brazil
1
Canada
1
Ukraine
1
Morocco
1
EA
1
New Zealand
1
Croatia
1
Peru
1
Israel
1
Chile
1
Portugal
1
Taiwan
1
Jordan
1
Mexico
1
Australia
1
Costa Rica
1
Ecuador
1
South Africa
1
Colombia
1
Lithuania
1
Tunisia
1
Slovenia
1
Hungary
1
European Union
47. List of Rozlytrek drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10738037 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11091469 | GENENTECH INC | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 15, 2026 |
| New Chemical Entity Exclusivity (NCE) | Aug 15, 2024 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 2023-08-16
Market Authorisation Date: 15 August, 2019
Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of colorectal cancer that has a neurotr...
Dosage: CAPSULE;ORAL
ROZLYTREK family patents
4
United States
3
European Union
2
Japan
1
Korea, Republic of
1
Poland
1
China
1
Spain
1
Hong Kong
1
Israel
1
Canada
1
Brazil
1
Mexico
1
Australia
48. List of Saxenda drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659 (Pediatric) | NOVO | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Dec 4, 2023 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 23 December, 2014
Treatment: Cardiovascular outcomes trial of liraglutide 1.8 mg in patients with type 2 diabetes and cardiovascular disease
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
5
European Union
2
United States
1
Spain
1
Philippines
1
Denmark
1
RS
1
Poland
1
China
1
Russia
1
Brazil
1
Canada
1
Morocco
1
Japan
1
Croatia
1
Korea, Republic of
1
Israel
1
Chile
1
Portugal
1
Mexico
1
Australia
1
South Africa
1
Slovenia
1
Hungary
49. List of Sunlenca drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10071985 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10654827 | GILEAD SCIENCES INC | Therapeutic compounds |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 2026-12-22
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: SOLUTION;SUBCUTANEOUS
50. List of Sunosi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11439597 | AXSOME MALTA | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: NA
Dosage: TABLET;ORAL
SUNOSI family patents
6
United States
1
Korea, Republic of
1
China
1
Russia
1
Philippines
1
Chile
1
Israel
1
Canada
1
Singapore
1
Mexico
1
Japan
1
Australia
1
Denmark
1
European Union
51. List of Sunosi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10512609 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| US10195151 | JAZZ | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
Sep, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
| Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (osa)
Dosage: TABLET;ORAL
SUNOSI family patents
6
United States
1
Korea, Republic of
1
China
1
Russia
1
Philippines
1
Chile
1
Israel
1
Canada
1
Singapore
1
Mexico
1
Japan
1
Australia
1
Denmark
1
European Union
52. List of Sutab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11382864 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleansing a colon and methods of using same |
Aug, 2037
(14 years from now) | |
| US10143656 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(14 years from now) | |
| US11033498 | BRAINTREE LABS | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Aug, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Nov 10, 2023 |
Drugs and Companies using MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE ingredient
Market Authorisation Date: 10 November, 2020
Treatment: Gastrointestinal tablets indicated for cleansing the colon in preparation for colonoscopy
Dosage: TABLET;ORAL
SUTAB family patents
4
United States
53. List of Tirosint-sol drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11096913 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(13 years from now) | |
| US10537538 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(13 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 15 December, 2016
Treatment: NA
Dosage: SOLUTION;ORAL
TIROSINT-SOL family patents
3
United States
3
European Union
1
Poland
1
Russia
1
Spain
1
China
1
Canada
1
Portugal
1
Denmark
1
Slovenia
1
Hungary
54. List of Tlando drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...
Dosage: CAPSULE;ORAL
55. List of Trikafta (copackaged) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11453655 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
| US10793547 | VERTEX PHARMS INC | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
Dec, 2037
(14 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11517564 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Dec, 2037
(14 years from now) | |
| US11179367 | VERTEX PHARMS INC | Pharmaceutical compositions for treating cystic fibrosis |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 8, 2024 |
| New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
| Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 2023-10-22
Market Authorisation Date: 21 October, 2019
Treatment: Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering daily e...
Dosage: TABLET;ORAL
TRIKAFTA (COPACKAGED) family patents
16
United States
5
Israel
4
Morocco
4
Australia
4
European Union
3
Brazil
3
Canada
3
EA
3
Japan
2
Uruguay
2
China
2
Argentina
2
Chile
2
Taiwan
2
Mexico
2
Colombia
1
Spain
1
Moldova, Republic of
1
Denmark
1
RS
1
Russia
1
Singapore
1
Croatia
1
Korea, Republic of
1
Peru
1
Portugal
1
Jordan
1
Ecuador
1
South Africa
1
Lithuania
1
Saudi Arabia
1
Slovenia
1
Hungary
56. List of Victoza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9968659 | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jan, 2037
(13 years from now) | |
|
US9968659 (Pediatric) | NOVO NORDISK INC | Liraglutide in cardiovascular conditions |
Jul, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jun 17, 2022 |
| Pediatric Exclusivity (PED) | Dec 17, 2022 |
Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient
Market Authorisation Date: 25 January, 2010
Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
5
European Union
2
United States
1
Spain
1
Philippines
1
Denmark
1
RS
1
Poland
1
China
1
Russia
1
Brazil
1
Canada
1
Morocco
1
Japan
1
Croatia
1
Korea, Republic of
1
Israel
1
Chile
1
Portugal
1
Mexico
1
Australia
1
South Africa
1
Slovenia
1
Hungary
57. List of Vitrakvi drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10045991 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(13 years from now) | |
| US11191766 | BAYER HEALTHCARE | Methods of treating pediatric cancers |
Apr, 2037
(13 years from now) | |
| US11484535 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| US10137127 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| US10668072 | BAYER HEALTHCARE | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Nov 26, 2025 |
| New Chemical Entity Exclusivity (NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 2022-11-26
Market Authorisation Date: 26 November, 2018
Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution; Method of treating...
Dosage: SOLUTION;ORAL
VITRAKVI family patents
16
United States
4
Chile
3
Morocco
3
Korea, Republic of
3
Tunisia
2
Philippines
2
Russia
2
China
2
Brazil
2
Canada
2
Ukraine
2
Singapore
2
Japan
2
Israel
2
Mexico
2
European Union
1
Dominican Republic
1
Argentina
1
Nicaragua
1
Peru
1
Taiwan
1
Georgia
1
Australia
1
Cuba
1
Costa Rica